Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration
/in Dendritic Cells, Glioblastoma, International Publications /von 2001-02-01 / Cancer Res. 2001 Feb;61(3):842-7Posttreatment histology and microcirculation status of osteogenic sarcoma after a neoadjuvant chemo- and radiotherapy in combination with local electromagnetic hyperthermia
/in Hyperthermia, International Publications /von 2001-02-01 / Onkologie 2001 Feb;24(1):55-8Dendritic cells and chronic hepatitis virus carriers
/in Chronic Virus Hepatitis, International Publications /von 2001-01-01 / Intervirology 2001;44(4):199-208Dendritic cells derived from multiple myeloma patients efficiently internalize different classes of myeloma protein
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2001-01-01 / Exp. Hematol. 2001 Jan;29(1):85-92In vitro induction of a bladder cancer-specific T-cell response by mRNA-transfected dendritic cells
/in Dendritic Cells, International Publications, Urothelial Carcinoma /von 2001-01-01 / J. Cancer Res. Clin. Oncol. 2001;127(3):203-6Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide
/in Dendritic Cells, International Publications, Urothelial Carcinoma /von 2001-01-01 / Clin. Cancer Res. 2001 Jan;7(1):23-31Effect of hyperthermia on AKR lymphoma variants differing in degree of malignancy
/in Hyperthermia, International Publications, Malignant Lymphoma /von 2001-01-01 / Cancer Invest. 2001;19(8):791-8Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report
/in Dendritic Cells, Glioblastoma, International Publications /von 2000-12-15 / Neurosurg Focus 2000 Dec;9(6):e8Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
/in Breast Cancer, Dendritic Cells, International Publications, Ovarian Cancer /von 2000-11-01 / Blood 2000 Nov;96(9):3102-8
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de